The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
1‐Methylnicotinamide (MNA), a primary metabolite of nicotinamide, exerts anti‐thrombotic activity mediated by a cyclooxygenase‐2/prostacyclin pathway
Open accessAbstract
Background and purpose: 1‐methylnicotinamide (MNA) has been considered to be an inactive metabolite of nicotinamide. Here we assessed the anti‐thrombotic activity of MNA in vivo. Experimental approach: Antithrombotic action of MNA was studied in normotensive rats with extracorporeal thrombus formation (thrombolysis), in renovascular hypertensive rats with intraarterial thrombus formation (arterial thrombosis) and in a venous thrombosis model in rats (venous thrombosis). Key results: MNA (3‐100 mg kg−1) induced a dose‐dependent and sustained thrombolytic response, associated with a rise in 6‐keto‐PGF 1 α in blood. Various compounds structurally related to MNA were either inactive or weaker thrombolytics. Rofecoxib (0.01‐1 mg kg−1), dose‐dependently inhibited the thrombolytic response of MNA, indomethacin (5 mg kg−1) abolished it, while L‐NAME (5 mg kg−1) were without effect. MNA (3–30 mg kg−1) also reduced arterial thrombosis and this effect was abrogated by indomethacin (2.5 mg kg−1) as well as by rofecoxib (1 mg kg−1). MNA, however, did not affect venous thrombosis. In vitro MNA did not modify platelet aggregation nor induce vasodilation. Conclusions and implications: MNA displayed a profile of anti‐thrombotic activity in vivo that surpasses that of closely related compounds. MNA inhibited platelet‐dependent thrombosis by a mechanism involving cyclooxygenase‐2 and prostacyclin. Our findings suggest that endogenous MNA, produced in the liver by nicotinamide N‐methyltransferase, could be an endogenous activator of prostacyclin production and thus may regulate thrombotic as well as inflammatory processes in the cardiovascular system. British Journal of Pharmacology (2007) 152, 230–239; doi:10.1038/sj.bjp.0707383
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bieganowski, P., & Brenner, C. (2004) · Cell · doi:10.1016/s0092-8674(04)00416-7 · Cited by 750
Gryglewski, R. J., Moncada, S., & Palmer, R. M. J. (1986) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.1986.tb14586.x · Cited by 200
Cited by
Nicotinamide N -Methyltransferase: More Than a Vitamin B3 Clearance Enzyme
Pissios, P. (2017) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2017.02.004 · Cited by 259
Hong, S., Moreno-Navarrete, J. M., Wei, X., Kikukawa, Y., Tzameli, I., Prasad, D., Lee, Y., Asara, J. M., Fernandez-Real, J. M., Maratos-Flier, E., et al. (2015) · Nature Medicine · doi:10.1038/nm.3882 · Cited by 257
Possible Adverse Effects of High-Dose Nicotinamide: Mechanisms and Safety Assessment
Hwang, E., & Song, S. (2020) · Biomolecules · doi:10.3390/biom10050687 · Cited by 144
Nicotinamide N-Oxidation by CYP2E1 in Human Liver Microsomes
Real, A. M., Hong, S., & Pissios, P. (2013) · Drug Metabolism and Disposition · doi:10.1124/dmd.112.049734 · Cited by 44
Metadata
- Authors
- Chlopicki, S., Swies, J., Mogielnicki, A., Buczko, W., Bartus, M., Lomnicka, M., Adamus, J., & Gebicki, J.
- Venue
- British Journal of Pharmacology
- Publisher
- Wiley
- Published
- 2007-09
- Volume
- 152
- Issue
- 2
- Pages
- 230-239
- ISSN
- 0007-1188 (ISSN-L)
- 1476-5381
- OpenAlex
- W1988122231
- Cited by
- 196
- References
- 2
- FWCI
- 6.81
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: 1‐Methylnicotinamide (MNA), a primary metabolite of nicotinamide, exerts anti‐thrombotic activity mediated by a cyclooxygenase‐2/prostacyclin pathway. https://app.cochat.ai/papers/10.1038/sj.bjp.0707383
- The paper
- Chlopicki, S., Swies, J., Mogielnicki, A., Buczko, W., Bartus, M., Lomnicka, M., Adamus, J., & Gebicki, J. (2007). 1‐Methylnicotinamide (MNA), a primary metabolite of nicotinamide, exerts anti‐thrombotic activity mediated by a cyclooxygenase‐2/prostacyclin pathway. British Journal of Pharmacology. https://doi.org/10.1038/sj.bjp.0707383
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.